The estimated Net Worth of Frederick M. Hudson is at least $1.65 Million dollars as of 15 November 2023. Mr. Hudson owns over 9,093 units of Supernus Pharmaceuticals Inc stock worth over $1,032,819 and over the last 13 years he sold SUPN stock worth over $259,151. In addition, he makes $359,953 as Independent Director at Supernus Pharmaceuticals Inc.
Frederick has made over 4 trades of the Supernus Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 9,093 units of SUPN stock worth $259,151 on 15 November 2023.
The largest trade he's ever made was selling 9,093 units of Supernus Pharmaceuticals Inc stock on 15 November 2023 worth over $259,151. On average, Frederick trades about 986 units every 132 days since 2012. As of 15 November 2023 he still owns at least 33,231 units of Supernus Pharmaceuticals Inc stock.
You can see the complete history of Mr. Hudson stock trades at the bottom of the page.
Frederick M. Hudson CPA serves as Independent Director of the Company. Mr. Hudson retired as a partner in the accounting firm of KPMG LLP in 2006 after a 37 year career with the firm. During Mr. Hudson's career with KPMG, he was the partner in charge of the health care audit practice for the Washington—Baltimore business unit, and held leadership positions for serving the middle market practice and due diligence and mergers and acquisitions services. He was also a leader of the health care audit practice for the Mid-Atlantic area of KPMG, and served as national account lead partner and venture capital liaison partner. Mr. Hudson currently chairs the audit committee of the board of directors of scPharmaceuticals, Inc., a publicly traded pharmaceutical company. From 2014 to 2019, Mr. Hudson was on the board of directors of Aradigm Corporation, a publicly traded specialty pharmaceutical company, and was also chair of the audit committee and a member of several other board committees. He chairs the finance committee of the board of directors of GBMC Healthcare, Inc. and its affiliate, Greater Baltimore Medical Center, where he was the prior chair of the audit committee. He was previously on the board of directors and the audit committee chair of Educate, Inc., Woodhaven Holding Corp., Vicor Technologies, Inc., and Paradigm Management Services LLC; and a member of the board of directors and the compliance committee of Maxim Healthcare Services, Inc. Mr. Hudson received a B.S. in Accounting from Loyola University Maryland and is a Certified Public Accountant (retired). Mr. Hudson's extensive accounting and health care audit experience qualify him to serve as a director.
As the Independent Director of Supernus Pharmaceuticals Inc, the total compensation of Frederick Hudson at Supernus Pharmaceuticals Inc is $359,953. There are 8 executives at Supernus Pharmaceuticals Inc getting paid more, with Jack Khattar having the highest compensation of $8,123,130.
Frederick Hudson is 74, he's been the Independent Director of Supernus Pharmaceuticals Inc since 2010. There are 2 older and 14 younger executives at Supernus Pharmaceuticals Inc. The oldest executive at Supernus Pharmaceuticals Inc is John Siebert, 80, who is the Independent Director.
Frederick's mailing address filed with the SEC is C/O SCPHARMACEUTICALS INC, 25 BURLINGTON MALL ROAD, SUITE 203, BURLINGTON, MA, 01803.
Over the last 13 years, insiders at Supernus Pharmaceuticals Inc have traded over $37,265,765 worth of Supernus Pharmaceuticals Inc stock and bought 16,600,700 units worth $83,216,588 . The most active insiders traders include Forest Baskett, Scott D Sandell und Peter J Barris. On average, Supernus Pharmaceuticals Inc executives and independent directors trade stock every 30 days with the average trade being worth of $4,263,834. The most recent stock trade was executed by Jack A. Khattar on 3 September 2024, trading 21,000 units of SUPN stock currently worth $652,680.
pioneering new medicines in neurology and psychiatry with more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (cns) disorders. in 2013 we launched oxtellar xr® and trokendi xr®, two novel neurology products for the treatment of epilepsy. we are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (adhd) and its coexisting disorders, and depression. we are developing differentiated products by leveraging our proprietary and in-licensed technologies. we use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.
Supernus Pharmaceuticals Inc executives and other stock owners filed with the SEC include: